Cytokines are essential regulatory components of the immune system and their aberrant levels 56 have been linked to many disease states. Despite increasing evidence that cytokines operate in 57 concert, many of the physiological interactions between cytokines, and the shared genetic 58 architecture that underlie them, remain unknown. Here we aimed to identify and characterise 59 genetic variants with pleiotropic effects on cytokinesto do this we performed a multivariate 60 genome-wide association study on a correlation network of 11 circulating cytokines measured 61 in 9,263 individuals. Meta-analysis identified a total of 8 loci significantly associated with the 62 cytokine network, of which two (PDGFRB and ABO) had not been detected previously. 63
Introduction
Cytokines are signalling molecules secreted by cells that are central to multiple physiological 70 functions, especially immune regulation (1). Broadly-speaking, cytokines include chemokines 71 that drive movement of cells, and growth factors that drive cell growth and proliferation. 72
Changes in circulating cytokine levels have been associated with infection (2), autoimmune 73 diseases (3), malignancies (4), as well as atherosclerosis and cardiovascular disease (5,6). The 74 expression of cytokines can be strongly regulated by genetic variation (7), and several studies 75 have identified cis-acting genetic variants associated with circulating levels of certain 76 cytokines and their receptors under various conditions (8-10). These initial studies laid the 77 foundation for genetic investigation of circulating cytokine levels at a scale and breadth that 78 may improve our understanding of individual differences in immune response, inflammation, 79 infection and common disease susceptibility. 80 81 Despite cytokines operating in concert to facilitate immune regulation, genome-wide 82 association studies (GWAS) have typically focused on individual cytokines (11-18). The most 83 extensive cytokine GWAS to date separately analysed individual levels of 41 circulating 84 cytokines in approximately 8,000 individuals, identifying 27 distinct loci each associated with 85 at least one cytokine (19) . Others have identified loci influencing cytokine production in 86 response to pathogens (20,21). While these previous GWAS utilised a univariate framework, 87 analysing each cytokine separately, studies of related traits indicate a multivariate framework 88 can confer greater statistical power, for example by taking advantage of the tightly co-regulated 89 nature of both pro and anti-inflammatory cytokines. 90 91 Several methods for multivariate GWAS of correlated phenotypes have been developed (22-92 27) . Simulations have shown that multivariate analysis can result in increased power to detect 93 genetic associations with small or pleiotropic effects across phenotypes (22,28-30). These have 94 largely been conducted on metabolic traits where they have demonstrated a boost in statistical 95 power. For example, multivariate analysis of four lipid traits led to a 21% increase in 96 independent genome-wide significant variants compared to univariate analysis (23). Similar 97 findings were shown for other metabolic traits (24,31). Moreover, complex genotype-98 phenotype dependencies have been revealed when jointly testing rare variants with lipoprotein 99 traits (32). Notably, a multivariate GWAS of networks of highly correlated serum metabolites 100 was able to detect nearly twice the number of loci compared to univariate testing, with 101 downstream tissue-specific transcriptional analyses showing that the top candidate genes from 102 multivariate analysis were upregulated in atherosclerotic plaques (31) . 103
104
In this study, we focus on correlated immune traits by leveraging the correlation structure 105 within a network of 11 cytokines to perform a multivariate genome-wide scan in 9,263 106 individuals from three population-based cohorts. We then investigate the colocalisation of 107 cytokine-associated variants with those regulating gene expression in numerous tissues and 108 cell types, circulating protein and metabolite levels, haematological traits, and disease states. 109
Finally, we highlight and characterise variants as potential master regulator of the cytokine 110 network, with pleiotropic effects on production of inflammatory proteins, immune cell 111 function, lipoprotein and lipid levels, and cardiometabolic diseases. this study was to monitor the risk factors of cardiovascular disease in children and adolescents 125 from different regions of Finland. In the baseline study, conducted in five Finnish metropolitan 126 areas (Turku, Helsinki, Kuopio, Tampere and Oulu), a total of 3,596 children and adolescents 127 were randomly selected from the national public register, the details of which were described 128 in (33). A total of 2,204 participants responded to the 2007 follow-up study (YFS07), for which 129 8,800 individuals, within the age group of 25-74 years, chosen from the national population 136 information system. This study utilised samples from the 1997 (FINRISK97) and 2002 137 (FINRISK02) collections, which recruited individuals from five or six (for FINRISK02) major 138 regional and metropolitan areas of Finland: the provinces of North Karelia, Northern Savo, 139 The Illuminus clustering algorithm was used for genotype calling (35) and quality control (QC) 160 was performed using the Sanger genotyping QC pipeline. This included removing SNPs and 161 samples with > 5% genotype missingness followed by removal of samples with gender 162 discrepancies. Genotypes were then imputed with IMPUTE2 (36) using the 1000 Genomes 163 Phase 1 version 3 as the reference panel followed by removal of SNPs with call rate < 95%, 164 imputation "info" score < 0.4, minor allele frequency < 1%, and Hardy-Weinberg equilibrium 165 P-value < 5 × 10 -6 . Instances where data was generated using different genotyping platforms, 166 overlapping SNPs were merged using PLINK version 1.90 software (https://www.cog-167 genomics.org/plink2) (37). A total of 6,664,959, 7,370,592 and 6,639,681 genotyped and 168
imputed SNPs passed quality control in YFS, FINRISK97 and FINRISK02, respectively. 169
Cryptic relatedness was assessed using identity by descent (IBD) estimates and in cases where 170 the pi-hat relatedness was greater than 0.1, one of the two individuals was randomly removed 171 (N=44 for YFS, N=291 for FINRISK97, and N=39 for FINRISK02). Genetic PCs were 172 obtained through principal component analysis (PCA) using FlashPCA (38) the Human Cytokine 21-plex assay system. All assays were performed in accordance with the 183 manufacturer's instructions, except that the amount of beads, detection antibodies, and 184 streptavidin-phycoerythrin conjugate were used at half their recommended concentration. 185 The analysis was limited to 18 cytokines (Table S1) assayed in all three cohorts. Although 195
Interleukin 1 receptor, type I (IL-1Ra) was assayed in all three cohorts, it was excluded from 196 the analyses due to its inconsistent Pearson correlation pattern with other 18 cytokines across 197 the three datasets. 198 199 Before normalisation, cytokine data was subset to individuals with matched genotype data in 200 YFS07 (N=2,018), FINRISK97 (N=5,728), and FINRISK02 (N=2,775). We excluded 201 individuals in YFS07 reporting febrile infection in the two weeks prior to blood sampling 202 (N=92). To identify extreme outlier samples, PCA was performed on the log2 transformed 203 cytokine values using the missMDA R package (39). This method first imputed the missing 204 cytokine values using a regularised iterative PCA algorithm implemented in the imputePCA 205 function, before performing PCA. Three and two outlier samples were removed from 206 FINRISK97 and FINRISK02 respectively. Based on IBD analysis described above, 44 207 (YFS07), 291 (FINRISK97), and 39 (FINRISK02) individuals were also removed. After 208 filtering, a total of 1,843, 5,434 and 1,986 individuals passed quality control in YFS07, 209 FINRISK97 and FINRISK02, respectively, and these were used for downstream analysis. 210
211
Since all 18 cytokines displayed non-Gaussian distributions, we performed normalisation of 212 cytokine levels. For YFS07, the lower limit of detection (LOD) was available for each 213 cytokine. Reported values that were below the LOD were indistinguishable from background 214 noise signals or instrument error (40), and were excluded and treated as missing. For 215 FINRISK97 and FINRISK02, the detection limits were not available; however, it was observed 216 that these two datasets exhibited a bimodal distribution, with the leftmost peak below the 217 expected LOD when compared to the YFS dataset. Individuals in the leftmost peak were 218 therefore set to missing. The log2-transformed cytokine values were then normalised to follow 219 standard Gaussian distributions (with mean of 0 and sd of 1) using rank-based inverse normal 220 transformation (rntransform) as implemented in the GenABEL R package (41). For each study 221 group, residuals for all cytokines were calculated by regressing the normalised cytokine values 222 on age, sex, BMI, lipid and blood pressure medication, pregnancy status (FINRISK97), and 223 the first 10 genetic PCs using a multiple linear regression model. 224
225
Detection of groups of correlated cytokines was done in FINRISK97, the cohort with the 226 largest sample size. Pairwise Pearson correlation was performed amongst residuals of 18 227 cytokines. These cytokines were then subjected to hierarchical clustering, with one minus the 228 absolute correlation coefficient used as the dissimilarity metric. We then defined a cytokine 229 networka group of 11 cytokines that were moderate-to highly-correlated (r > 0.57)for 230 subsequent use in the multivariate analysis. Bayesian colocalisation tests between cytokine network-associated signals and the following 270 trait-and disease-associated signals were performed using the COLOC R package (45). For 271 whole blood cis-eQTLs, we downloaded publicly-available summary data from the eQTLGen 272 Consortium portal (http://www.eqtlgen.org/). The eQTLGen Consortium analysis is the largest 273 meta-analysis of blood eQTLs to date and comprises of 31,684 blood and PBMC samples from 274 a total of 37 datasets (46). For immune cell cis-eQTLs, we either generated cis-eQTL summary 275 data in resting B-cells (47), resting monocytes (48), and stimulated monocytes with interferon-276 γ or lipopolysaccharide (48), or obtained publicly-available cis-eQTL summary data generated 277 by the BLUEPRINT consortium in neutrophils and CD4 + T-cells (49). For cis-eQTL mapping 278 in B-cells and monocytes (resting and stimulated), information on accessing the raw gene 279 expression and genotype data, data pre-processing, and cis-eQTL analysis has been described 280 in a previous study (50). The BLUEPRINT immune cell summary statistics was downloaded 281 from: ftp://ftp.ebi.ac.uk/pub/databases/blueprint/blueprint_Epivar/. For protein QTLs, we used 282 publicly-available SomaLogic plasma protein GWAS summary statistics from the INTERVAL 283 study (17). For disease or complex trait associations, we compiled summary statistics of 185 284 diseases and quantitative traits from GWAS studies conducted in 285
European ancestry individuals, which were accessed from the UK biobank (Table S10) , or 286 downloaded from either ImmunoBase (https://www.immunobase.org/), the NHGRI-EBI 287 GWAS Catalog (https://www.ebi.ac.uk/gwas/), or LD Hub (http://ldsc.broadinstitute.org/). 288
Here, we only considered immune-related and cardiometabolic diseases. For each cytokine 289 network locus, we only tested traits or diseases with the minimum association P-value < 1 × 290 10 -6 at this locus. COLOC requires either beta-coefficients and its variance, or P-values, for 291 each SNP, in addition to MAF and sample size. Since PLINK multivariate did not produce beta 292 values and standard errors, we instead used meta-analysed P-values for the multivariate 293 cytokine GWAS summary data. For each association pair assessed for colocalisation, SNPs 294 within 200kb of the lead multivariate cytokine GWAS SNP were considered. COLOC 295 (coloc.abf) was run with default parameters and priors. COLOC computed posterior 296 probabilities for the following five hypotheses: PP0, no association with trait 1 (cytokine 297 GWAS signal) or trait 2 (e.g. eQTL signal); PP1, association with trait 1 only (i.e. no 298 association with trait 2); PP2, association with trait 2 only (i.e. no association with trait 1); PP3, 299 association with trait 1 and trait 2 by two independent signals; PP4, association with trait 1 and 300 trait 2 by shared variants. In practice, evidence of colocalisation were defined by 301 PP3 + PP4 ≥ 0.99 and PP4/PP3 ≥ 5, a cut off previously suggested (50). had genome-wide genotype data and quantitative measurements of 18 cytokines (Table S1) . 312
Characteristics of the study cohorts are summarised in Table 1 . Genotypes for the three 313 datasets were imputed with IMPUTE2 (36) using the 1000 Genomes Phase 1 version 3 of the 314 reference panel. After quality control, a total of 6,022,229 imputed and genotyped SNPs were 315 available across all cohorts. Cytokine levels were measured in serum and plasma using Bio-316
Plex ProTM Human Cytokine 27-plex and 21-plex assays, then subsequently normalised and 317 adjusted for covariates including age, sex, BMI, pregnancy status, blood pressure lowering 318 medication, lipid lowering medication, and population structure (Methods). An overview of 319 the study is shown in Figure 1 . 320 321 A correlation network of circulating cytokines 322 To characterise the correlation structure of circulating cytokines, we utilised the largest dataset 323 available (FINRISK97) and the set of 18 cytokines overlapping all three cohorts. IL-18 was 324 very weakly correlated with other cytokines (Figure 2A) , while TRAIL, SCF, HGF, MCP-1, 325 EOTAXIN and MIP-1b showed moderate correlation with the others. A distinct set of 11 326 cytokines showed high correlation amongst themselves (median r=0.75). In the smaller cohorts 327 (YFS07 and FINRISK02), the cytokine correlation structure was similar but weaker (Figure 328 S1), with the set of 11 cytokines also showing relatively high correlation (YFS07 median 329 r=0.42; FINRISK02 median r=0.46). We utilised this set of 11 cytokines (denoted below as the 330 cytokine network) for multivariate association analysis. Multivariate genome-wide association analysis for cytokine loci 340 We performed a multivariate GWAS on the cytokine network in each cohort separately, then 341 cohort-level results were combined using meta-analysis (Methods). Since one hypothesis test 342 (corresponding to the cytokine network) was performed for each SNP, a genome-wide 343 significance threshold of P < 5 × 10 -8 was used. Minimal inflation was observed for the cohort-344 level and meta-analysis test statistics with lambda (λ) inflation ranging between 1.00-1.02 345 (Figure S2A -D) . 346
347
We identified 8 loci reaching genome-wide significance for the cytokine network ( Figure 2B ; 348 Table 2 ). The strongest association was rs7767396 (meta-P-value = 6.93 × 10 -306 ), a SNP 349 located 172kb downstream of vascular endothelial growth factor A (VEGFA) (Figure S3A) . 350
The VEGFA locus was previously identified in GWAS for individual cytokine levels including 351 VEGF-A, IL-7, IL-10, IL-12, and IL-13 (14,19). Consistent with these earlier results, we found 352 that VEGF-A, IL-10, and IL-12 were the top three cytokines based on their trait loadings 353 (relative contribution of each cytokine to the multivariate association result) in each cohort and 354 also significantly associated with this locus in the univariate scans (Figure S4A) . cytokine with the highest loading at each of these loci was consistent with those previously 360 identified in univariate analysis (Figure S4B -E) . 361
362
The multivariate GWAS also detected novel cytokine associations not identified in any 363 previous univariate tests of these cytokines. These were three loci with genic lead SNPs in the 364 candidate genes F5, PDGFRB, and ABO. The lead variant at the F5 locus (rs9332599; meta-365 P-value = 7.17 ×10 -12 ) is located in intron 12 of F5 (Figure S3F) . At the platelet-derived 366 growth factor receptor-beta (PDGFRB) locus, the lead variant rs2304058 (meta-P-value = 4.06 367 × 10 -9 ) is within intron 10 of PDGFRB (Figure S3G) . At the ABO locus, the lead variant 368 rs550057 (meta-P-value = 2.75 × 10 -8 ) is within the first intron of ABO (Figure S3H) ; 369 furthermore, rs550057 is located ~1.6 kb upstream of the erythroid cell specific enhancer, 370 which contains a GATA-1 transcription factor binding site and has been shown to enhance the 371 transcription of the ABO gene (55). 372
373
To investigate the presence of multiple independently associated variants at each of the eight 374 loci, we performed stepwise conditional multivariate meta-analysis. Three loci (SERPINE2, 375 VEGFA, and PCSK6) exhibited evidence of multiple independent signals (Table S2) . In 376 addition to the lead variants (rs6722871, rs7767396, rs11639051) at each of these three loci, 377 we identified additional association signals (rs55864163; SERPINE2, meta-Pcond. = 9.03 × 10 -378 29 ; rs112215592, SERPINE2, meta-Pcond = 2.10 × 10 -12 ; rs4714729; VEGFA, meta-Pcond = 7.49 379 × 10 -10 ; rs6598475, PCSK6, meta-Pcond = 2.63 × 10 -17 ), which were independently associated 380 with the cytokine network. We also performed conditional univariate analysis that adjusted for 381 the lead multivariate SNPs, which were either the same lead univariate SNPs or in high LD (r 2 382 = 0.99). This univariate analysis also uncovered the same secondary signal at the VEGFA locus 383 in association with VEGFA cytokine levels (rs4714729; meta-Pcond = 8.8 × 10 -13 ) ( Table S2) . 384
385

Colocalisation of cytokine variants with cis-eQTLs in whole blood
386
To characterise the regulatory effects of the multivariate cytokine-associated loci, we queried 387 the largest publicly-available set of results for whole blood cis-eQTLs from a meta-analysis of 388 31,684 individuals, which was obtained from the eQTLGen Consortium database (46). We 389 found SNPs, lead or LD-proxy (r 2 >0.5), at seven of the eight cytokine loci (ABO, F5, PCSK6, 390 PDGFRB, SERPINE2, VEGFA, VLDLR) with cis-regulatory effects (P-value < 1 × 10 −6 ) on 391 gene expression (a total of 17 unique genes) in blood (Table S3 ). Using Bayesian 392 colocalisation analysis, we further demonstrated that associations at three of these loci 393 colocalised with cis-eQTLs for ABO, PCSK6, and SERPINE2 expression ( Figure 3A -C (Table S5 ). Three out of the eight 402 cytokine network loci harboured cis-eQTLs (P-value < 1 × 10 −6 ) in at least one immune cell 403 type, in either stimulated or non-stimulated state ( Table S6) . For example, SNPs at the 404 SERPINE2 locus were reported to have cis-eQTL effects across multiple immune cell types, 405 including B-cells, CD4 + and CD8 + T-cells (Table S6) . 406 407 Further, colocalisation analysis showed that the cytokine network variants at SERPINE2 had 408 strong evidence of sharing a causal variant with SERPINE2 cis-eQTLs in CD4 + T-cells and B-409 cells, similar to the colocalisation we observe in whole blood (Figure 3B; Table S7 ). 410 411
Colocalisation of cytokine variants with immune cell-specific cis-eQTLs
Colocalisation of cytokine variants with plasma protein QTLs
412
To investigate protein-level effects of cytokine network variants, we utilised plasma protein 413 QTLs (pQTLs) from the INTERVAL study (17). Colocalisation analysis, considering only 414 pQTLs with association P-value < 1 × 10 -6 , showed all the eight cytokine network loci had 415 strong evidence of shared causal variants with plasma levels of a total of 146 proteins (out of 416 the 215 tested) ( Table S8 ). Of these, the ABO and ZFPM cytokine network loci strongly 417 colocalised with pQTL signals for 55 (out of 81) and 87 (out of 98) proteins, respectively 418 (Table 3; Table S8 ). Of these, 14 and 75 proteins shared the same causal lead pQTLs with the 419 lead cytokine network variants at the ABO (rs550057) and ZFPM2 (rs6993770) loci, 420 respectively, suggesting these variants have widespread effects. 421
422
The ABO locus colocalised with pQTLs for several membrane proteins (B3GN2, endoglin, 423 GOLM1, OX2G, TPST2) and cell surface receptors (IL-3RA, LIFR, IGF-I R, HGF receptor). 424
ABO colocalisation was also observed with pQTLs for adhesion and immune-related molecules 425 involved in leukocyte recruitment, cell adhesion, and transmigration, including sGP130, 426 sICAM-1, sICAM-2, LIRB4, and P-selectin ( Table 3; Table S8 ). At the ZFPM2 locus, 427 colocalisation was seen with pQTLs for proteins generally found in platelet granules (e.g. 428 VEGFA, PDGF-AA, PDGF-BB, PDGF-D, angiopoietin, P-selectin). At the SERPINE2 locus, 429 we observed that in addition to colocalising with the cis-eQTL signal for SERPINE2 430 expression, the cytokine network-associated variants colocalised with the cis-pQTL variants 431 for SERPINE2 protein levels (Table S8) . Likewise, the VEGFA locus colocalised with a cis-432 pQTL for VEGFA, and the PDGFRB locus with a cis-pQTL for PDGFRB. 433 434
Relationships of cytokine network variants with complex traits and diseases 435
Using the NHGRI GWAS Catalog (57,58), we found that, across all eight cytokine network 436 loci, 55 SNPs matched SNPs previously associated with quantitative traits and diseases. (Table  437 S9). The lead cytokine network variant at ZFPM2 (rs6993770) has previously been associated 438 with various platelet traits, including platelet count, distribution width, plateletcrit (total 439 platelet mass) and mean volume (17,59) ( Table S9) . 440 441 Next, GWAS summary statistics from a broad range of traits and diseases (Table S10) , 442 including hematopoietic traits, circulating metabolites, immune-and cardiometabolic-related 443 diseases were compiled for colocalisation analysis with the cytokine network loci. The two 444 cytokine network-associated loci, ABO and ZFPM2, exhibited strong evidence of 445 colocalisation for several traits and diseases. The ZFPM2 locus not only colocalised with 446 signals for several platelet trait associations, but also with other haematological trait-associated 447 signals including white blood cell counts, and specifically neutrophil and basophil counts 448 (Table 3 ; Table S11 ). The ABO locus showed colocalisation with various QTLs for 449 haematological traits including red blood cell traits (haemoglobin concentration, red blood cell 450 count, and hematocrit) and white blood cell counts, including granulocyte count and 451 specifically eosinophil count ( Table 3; Table S11 ). This is consistent with the ABO locus being 452 identified as a pQTL for proteins involved in leukocyte activation as identified previously. 453
Cytokine network variants at the ABO locus colocalised with those of intermediate density, 454 low density, and very low-density lipoprotein subclasses as well as glycosylated haemoglobin 455 (HbA1c) ( Table 3; Table S11 ), suggesting both inflammatory and metabolic effects. Notably, 456 the same cytokine network variants at the ABO locus also strongly colocalised with signals 457 associated with coronary artery disease (CAD), pulmonary embolism, ischemic stroke, and 458 type 2 diabetes (T2D) ( Table 3, Table S11 ). showing that these 11 circulating cytokines are positively correlated in the general population. 474 Therefore, at the population level, it is more likely that an equilibrium in circulating levels of 475 disparate cytokines exists, possibly maintained by counter-regulatory mechanisms. 476
477
Our multivariate GWAS meta-analysis identified eight loci associated with the cytokine 478 network; confirming six previously-reported associations for circulating cytokine levels 479 (14, 16, 19) as well as uncovering two additional signals (PDGFRB and ABO), empirically 480 demonstrating the statistical power of multivariate approaches. Further, integrative genetic 481 analyses revealed evidence for shared genetic influences between these loci, molecular QTLs, 482 and complex trait and disease associations. This study identified several regions harbouring 483 cytokine-associated signals that colocalise with whole blood and/or immune cell-specific cis-484 eQTLs for a number of genes, including SERPINE2, ABO, and PCSK6, suggesting these genes 485 are possible candidates underlying the collective expression of cytokines in the cytokine 486 networkor vice versa. Our findings also highlight that the cytokine network associations at 487 the pleiotropic loci, ABO and ZFPM2, overlap with signals associated with multiple traits, 488 including cardiometabolic diseases, immune-related proteins, and platelet traits. 489 490 SERPINE2 encodes protease nexin-1, an inhibitor of serine proteases such as thrombin and 491 plasmin, and is therefore implicated in coagulation, fibrinolysis and tissue remodelling (60). It 492 shares similar functions with its better-known homolog SERPINE1, or plasminogen activator 493 inhibitor-1 (PAI-1), the elevation of which is associated with thrombosis and cardiovascular 494 risk (60). However, there is also evidence that SERPINE2 has pleiotropic roles in immune and 495 inflammatory regulation, that could be either dependent or independent of its function as a 496 serine protease. It is expressed in many tissue types, and its expression can be induced by pro-497 inflammatory cytokines such as IL-1α (61,62). Conversely, SERPINE2 can itself influence 498 inflammatory status: SERPINE2 is a candidate susceptibility gene for chronic obstructive 499 pulmonary disease, and SERPINE2-knock-out mice exhibited extensive accumulation of 500 lymphocytes in the lungs, through a mechanism linked to thrombin and NFκB activation (62). 501
We observed in our data that the cytokine network associations overlapped with the SERPINE2 502 pQTL signal. Moreover, using immune cell-specific cis-eQTL data, we further demonstrated 503 colocalisation between the cytokine network and SERPINE2 cis-eQTL signals specifically in 504 CD4 + T-cells and B-cells. This suggests that the association between SERPINE2 and the 505 cytokine network at this locus is at least partially-driven by lymphocytic expression -506 consistent with SERPINE2 itself influencing chemotaxis and recruitment of lymphocytes (62). 507
Our analyses demonstrate that the importance of SERPINE2 in regulating immune and 508 inflammatory processes is potentially greater than previously anticipated, and warrants further 509 targeted research. 510 511 Like SERPINE2, the ABO locus has widespread pleiotropic effects. The most well-known 512 function of ABO is its determination of blood group. The human ABO gene has three major 513 alleles (A, B, and O) that determine ABO blood type. The A and B alleles encode for distinct 514 "A" versus "B" glycosyltransferases that add specific sugar residues to a precursor molecule 515 (H antigen) to form A versus B antigens, respectively (63). The O allele results in a protein 516 without glycosyltransferase activity (63). The lead cytokine-associated variant rs550057 and 517 its proxies in moderate LD (r 2 = 0.6; rs507666, rs687289) have been previously shown to 518 determine the ABO allele (64), but they have also been associated with circulating levels of 519 inflammatory proteins such sICAM-1, P-selectin , and ALP (17,65,66). Our study showed that 520 cytokine network associations at the ABO locus share colocalised signals with a host of other 521 proteins and traits, including lipoproteins (IDL, LDL, VLDL), proteins of immune function, 522 immune cell subsets, and cardiometabolic diseases ( Table 3) , highlighting the potential for 523 shared molecular etiology amongst these traits. Our analyses highlight the potential genetic 524 basis for numerous previous observations linking ABO blood group to an array of similar traits 525 and phenotypes (18,67-71). 526 527 It could therefore be speculated that the ABO gene influences the risk of cardiometabolic 528 disease due to its involvement in multiple inflammatory, haemostatic and metabolic processes; 529 however, our current understanding of the mechanisms behind this remains unclear. For 530 instance, non-O blood groups have been associated with increased risk of both cardiovascular 531 disease, venous thromboembolism, stroke, and T2D (68,72). However, the O blood group has 532 itself been linked to elevated IL-10 and worse outcomes given existing coronary disease (risk 533 of cardiovascular death, recurrent myocardial infarction and all-cause mortality) (64). Other 534 studies have suggested a role for von Willebrand factor (VWF), a coagulative factor which also 535 expresses ABO antigensin particular, the O phenotype is associated with lower VWF, which 536 may explain reduced thrombotic and cardiovascular risk (64,73). It has been suggested that the 537 link between ABO blood group type and venous thromboembolism (VTE) is potentially driven 538 by VWF and Factor VIIInon-O blood group individuals presented a higher risk of venous 539 thromboembolism and had elevated levels of both VWF and Factor VIII (74,75). Also relevant 540 is the link between ABO and adhesion molecules such as E-selectin and sICAM-1 which are 541 overexpressed in inflammatory states (18,66,70,71). sICAM-1 is a known positive correlate 542 with cardiovascular disease; however, it is the A blood group, not O, that is associated with 543 reduced sICAM-1 levels, again complicating the picture (70). Inferring the exact causal 544 relationships amongst all these entities will require intricate follow-up experimental 545 investigation, involving simultaneous examination of all key players. It is particularly unclear 546 whether the link with cardiometabolic diseases may be due to its direct modification of H 547 antigen, or on the glycosyltransferase activity of the encoded enzyme on other proteins, or 548 some combination of both. In our study, formal causal inference (e.g. with Mendelian 549 Randomisation) was not possible because the corresponding multivariate beta-coefficients and 550 standard errors are not currently calculable and the locus itself has extensive pleiotropy. 551
552
The ZFPM2 locus has been associated with platelet traits (59), and our findings highlight its 553 importance as a determinant of platelet and angiogenic cytokine activity. ZFPM2 encodes a 554 zinc finger cofactor that regulates the activity of GATA4, a transcription factor reported to play 555 a critical function not only in heart development (76) but also modulation of angiogenesis. In 556 particular, GATA4 directly binds to the promoter of angiogenic factor VEGFA and regulates 557 its expression (77), and it has been shown that disruption of ZFPM2-GATA4 interaction alters 558 the expression of VEGFA and other angiogenesis-related genes (78). VEGFA and PDGFR-BB, 559 which are part of the cytokine network, have been found to be released via alpha granules of 560 activated platelets, and serum VEGFA levels correlate closely with blood platelet counts (79-561 81). In our study, we show that the cytokine-associated signal at the ZFPM2 locus colocalised 562 with GWAS signals for platelet traits and platelet proteins. The lead cytokine network SNP 563 rs6993770 has been reported to be a trans-eQTL in whole blood for gene products typically 564 found in platelets and their receptors (e.g. CXCL5, GP9, MYL9, VWF) (46). Collectively, 565 these findings suggest that this locus regulates the number and/or cytokine activity of 566 circulating platelets, and that this potentially occurs via interaction with GATA4 and regulation 567 of VEGFA. 568
569
In conclusion, our study illustrates the utility of multivariate analysis of correlated immune 570 traits and highlights potentially fruitful avenues of biological investigation for multivariate 571 genetic signals. Our results highlight that certain gene loci drive the expression of a cytokine 572 network with immune, inflammatory and tissue repair functions; and, simultaneously, these 573 loci are implicated in the regulation of other haemostatic and metabolic functions, with 574 relevance to human health and disease. This stresses the fact that the processes of inflammation, 575 haemostasis and repair often run concurrent with each other after injury, and that biological 576 Monocyte, platelet, plateletcrit (%), red cell distribution width
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